Smoking cessation by combined medication and counselling: a feasibility study in lung cancer patients.
Christian ReinhardtMarkus HardenChristoph Herrmann-LingenAchim RittmeyerStefan AndreasPublished in: BMC pulmonary medicine (2022)
In conclusion, our results suggest that smoking cessation is feasible in patients with newly diagnosed lung cancer. The observed abstinence rate is comparable to other patient cohorts. Furthermore, pharmacotherapy in addition to cancer therapy was safe and did not show novel side effects in these seriously ill patients. Thus, smoking cessation should be an integral part of lung cancer treatment. Trial registration The study was conducted in accordance with good clinical practice standards (GCP) and approved by the local ethics committee (16/3/14), the European PAS registry (EUPAS8748) and the German BfArM (NIS-Studien-Nr. 5508). All patients provided written informed consent before study enrollment.
Keyphrases
- smoking cessation
- newly diagnosed
- end stage renal disease
- replacement therapy
- ejection fraction
- cancer therapy
- prognostic factors
- peritoneal dialysis
- healthcare
- clinical trial
- randomized controlled trial
- clinical practice
- emergency department
- patient reported outcomes
- machine learning
- hiv infected
- human immunodeficiency virus
- deep learning
- health insurance
- antiretroviral therapy
- phase ii